Semglee Pen Recall; Prader-Willi Syndrome Drug Rejected; Resilience Good for Sex

The FDA announced that Mylan Pharmaceuticals is voluntarily recalling a batch of its non-interchangeable insulin glargine injection (Semglee) prefilled pens for possible missing labels.

In other FDA news, the agency turned down Levo Therapeutics’ investigational intranasal form of carbetocin (LV-101), which was developed as a treatment for hyperphagia, anxiety, and distress associated with Prader-Willi syndrome.

Women with obesity who lost about 7% of their body weight prior to fertility treatment didn’t seem to have any greater chance of having a healthy baby. (ScienceDaily)

Being more resilient was tied to more positive feelings of well-being and better sexual health among menopausal women. “Fortunately, this skill set can be strengthened, potentially representing another tool that clinicians can use to help women with sexual dysfunction,” said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society, in a statement. (Menopause)

The gut microbiome — and more specifically lower beta diversity and greater Actinobacteria — may contribute to cardiometabolic health and insulin sensitivity disparities for Black women. (PLoS One)

LG Chem announced that it launched a phase I clinical trial testing LC542019, an investigational drug aimed at improving desensitized insulin reaction in people with type 2 diabetes.

Gerald I. Shulman, MD, PhD, co-director of the Yale Diabetes Research Center, was the 2021 winner of the Manpei Suzuki International Prize for Diabetes Research.

Imcyse announced positive phase II findings from its IMPACT study testing its investigational proinsulin-derived Imotope, IMCY-0098, for the treatment and prevention of type 1 diabetes.